Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on May 27, 2026, with approximately 73% of outstanding shares represented, constituting a quorum. Stockholders voted to elect Ian Clark and Christi Shaw as Class II directors, who will serve until the 2029 annual meeting. Additionally, the appointment of BDO USA, P.C. as the independent registered public accounting firm for the year ending December 31, 2026, was ratified.

Kyverna Therapeutics, Inc. announced the appointment of Gregory Martini as its new Chief Financial Officer, effective May 18, 2026. Martini, who previously served as CFO of Ironwood Pharmaceuticals, will oversee Kyverna's financial strategy and operations as the company prepares for the potential commercialization of its lead therapy, miv-cel. His compensation package includes an annual salary of $525,000, a $300,000 sign-on bonus, and an option to purchase 325,000 shares of common stock.

Kyverna Therapeutics, Inc. announced the appointment of Greg Martini as its new Chief Financial Officer, effective May 18, 2026. Mr. Martini, previously SVP and CFO at Ironwood Pharmaceuticals, will lead Kyverna's financial strategy, capital allocation, and investor relations as the company advances its lead candidate, miv-cel, toward potential approval and commercialization. He succeeds Dr. Marc Grasso, who will provide consulting services for a smooth transition. In connection with his appointment, Mr. Martini received an inducement grant of an option to purchase 325,000 shares of common stock.

Kyverna Therapeutics announced that its management will present at two upcoming investor conferences. The company will participate in a fireside chat and investor meetings at the H.C. Wainwright 4th Annual Nasdaq BioConnect Conference on May 19, 2026. Additionally, Kyverna will deliver a corporate presentation and hold investor meetings at the Jefferies Global Healthcare Conference on June 3, 2026. Live webcasts of both presentations will be accessible via the investor relations section of Kyverna's website.

Kyverna Therapeutics reported a net loss of $39.7 million for the three months ended March 31, 2026, an improvement from the $44.6 million loss in the prior year. Research and development expenses decreased to $30.1 million, while general and administrative expenses rose. The company's cash and cash equivalents stood at $32.2 million, with total cash, cash equivalents, and marketable securities at $236.4 million, which management expects to fund operations for at least the next 12 months.

Kyverna Therapeutics announced the initiation of a rolling Biologics License Application (BLA) submission for miv-cel in Stiff Person Syndrome (SPS) following positive FDA alignment, with completion anticipated in Q4 2026. The company also reported first-quarter 2026 financial results, including a net loss of $39.7 million and $236.4 million in cash, cash equivalents, and marketable securities. Additionally, Kyverna provided updates on advancing its Phase 3 trial in generalized myasthenia gravis (gMG) and positive data in progressive multiple sclerosis (PMS), alongside the appointment of a Chief Commercial Officer.

Kyverna Therapeutics initiated a rolling Biologics License Application (BLA) submission for miv-cel in Stiff Person Syndrome (SPS) after a positive pre-BLA meeting with the FDA, gaining alignment on the regulatory path, including the sufficiency of the single-arm KYSA-8 trial. The company anticipates completing the submission in Q4 2026, seeking priority review. Additionally, Kyverna reported Q1 2026 financial results, including a net loss of $39.7 million and $236.4 million in cash, with a runway into 2028. Progress was also noted in gMG and PMS clinical trials, and Nadia Dac was appointed Chief Commercial Officer.

Kyverna Therapeutics, Inc. announced the appointment of Nadia Dac as its Chief Commercial Officer, effective May 4, 2026. Ms. Dac brings over 30 years of extensive commercial leadership experience in neurology and rare diseases, including successful product launches and building commercial organizations. She will be responsible for leading the commercial strategy and execution for miv-cel, Kyverna's lead CAR T-cell therapy, as the company prepares for a potential first approval in stiff person syndrome and transitions to a commercial-stage entity. In connection with her appointment, Ms. Dac was granted an inducement option to purchase 300,000 shares of common stock.

Kyverna Therapeutics announced positive clinical trial results for its drug miv-cel. On April 20, 2026, the company reported positive longer-term follow-up data from the Phase 2 portion of its KYSA-6 trial for miv-cel in generalized myasthenia gravis. The following day, April 21, 2026, Kyverna released positive primary analysis results from its KYSA-8 registrational trial of miv-cel in stiff person syndrome. The company hosted a conference call on April 22, 2026, to discuss these findings.

Kyverna Therapeutics, Inc. announced positive primary analysis results from its registrational trial, KYSA-8, for miv-cel (KYV-101) in stiff person syndrome (SPS). The trial demonstrated statistically significant and durable clinical benefit across all endpoints, with a single dose achieving robust and durable improvements in mobility. This positive outcome could significantly advance the development of miv-cel as a treatment for SPS.